Incyte Corp
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Holds 89.3x more cash than debt — a strong balance sheet.
Current Price
$96.91
+1.72%GoodMoat Value
$271.40
180.1% undervaluedIncyte Corp (INCY) Financial Statements
GoodMoat Analysis
Incyte Corp demonstrates strong fundamental quality with exceptional profitability and a pristine balance sheet. Revenue growth is robust, but the key question for a value investor is the durability of this growth beyond its core drug.
Read full analysis
INCY Computed Insights
Income Statement
Balance Sheet
Cash Flow Statement
INCY Financial Statements & Data
Incyte Corp (INCY) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Incyte Corp's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $5.36B. Gross profit (TTM) is $4.96B. EBITDA is $1.87B. Earnings per share (EPS) is $6.41. The P/E ratio is 13.47. Market capitalization is $19.29B.
Free cash flow (FCF) is $1.35B. FCF growth rate is 13.53%. EPS growth CAGR is 19.27%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Incyte Corp's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.